{"ModuleTitle": "Company Description", "CompanyName": "ChemoCentryx, Inc.", "Symbol": "CCXI", "Address": "850 MAUDE AVENUE, MOUNTAIN VIEW, California, 94043, United States of America", "Phone": "650-210-2900", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "ChemoCentryx is a biopharmaceutical company focused on the development and\r\ncommercialization of new medications targeted at inflammatory disorders,\r\nautoimmune diseases and cancer. Each of our drug candidates is designed to\r\nselectively block a specific chemoattractant receptor, leaving the rest of the\r\nimmune system intact. Our drug candidates are small molecules, which are orally\r\nadministered, and, if approved, could address unmet medical needs, including\r\nimproved efficacy, and offer significant quality of life benefits, since\r\npatients swallow a capsule or pill instead of having to visit a clinic for an\r\ninfusion or undergo an injection.\r\n\r\nIn November 2019, we announced positive topline data from the pivotal Phase III\r\nADVOCATE trial of avacopan, our lead drug candidate that is an\r\norally-administered selective complement 5a receptor inhibitor, for the\r\ntreatment of patients with anti-neutrophil cytoplasmic antibody-associated\r\nvasculitis, or ANCA vasculitis.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f10%2f0001564590-20-009787.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Catherine Lee Kelleher", "title": "Senior Vice President-Clinical Development"}, {"name": "Markus J. Cappel", "title": "Treasurer & Chief Business Officer"}, {"name": "Sangita Ghosh", "title": "Senior Vice President-Technical Operations"}, {"name": "Susan M. Kanaya", "title": "SVP, Chief Financial & Administrative Officer"}, {"name": "Thomas J. Schall", "title": "Chairman, President & Chief Executive Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}